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Abstract
Background: The BED IgG-Capture Enzyme Immunoassay (cBED assay), a test of recent HIV infection, has been used to
estimate HIV incidence in cross-sectional HIV surveys. However, there has been concern that the assay overestimates HIV
incidence to an unknown extent because it falsely classifies some individuals with non-recent HIV infections as recently
infected. We used data from a longitudinal HIV surveillance in rural South Africa to measure the fraction of people with non-
recent HIV infection who are falsely classified as recently HIV-infected by the cBED assay (the long-term false-positive ratio
(FPR)) and compared cBED assay-based HIV incidence estimates to longitudinally measured HIV incidence.
Methodology/Principal Findings: We measured the long-term FPR in individuals with two positive HIV tests (in the HIV
surveillance, 2003–2006) more than 306 days apart (sample size n= 1,065). We implemented four different formulae to
calculate HIV incidence using cBED assay testing (n= 11,755) and obtained confidence intervals (CIs) by directly calculating
the central 95th percentile of incidence values. We observed 4,869 individuals over 7,685 person-years for longitudinal HIV
incidence estimation. The long-term FPR was 0.0169 (95% CI 0.0100–0.0266). Using this FPR, the cross-sectional cBED-based
HIV incidence estimates (per 100 people per year) varied between 3.03 (95% CI 2.44–3.63) and 3.19 (95% CI 2.57–3.82),
depending on the incidence formula. Using a long-term FPR of 0.0560 based on previous studies, HIV incidence estimates
varied between 0.65 (95% CI 0.00–1.32) and 0.71 (95% CI 0.00–1.43). The longitudinally measured HIV incidence was 3.09 per
100 people per year (95% CI 2.69–3.52), after adjustment to the sex-age distribution of the sample used in cBED assay-based
estimation.
Conclusions/Significance: In a rural community in South Africa with high HIV prevalence, the long-term FPR of the cBED
assay is substantially lower than previous estimates. The cBED assay performs well in HIV incidence estimation if the locally
measured long-term FPR is used, but significantly underestimates incidence when a FPR estimate based on previous studies
in other settings is used.
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Introduction
To understand the dynamics of the HIV epidemic and to target
and evaluate interventions to prevent HIV infection, estimates of
HIV incidence at the population level are of prime importance.
HIV incidence estimates can be obtained through repeated HIV
testing of individuals in longitudinal surveillances. Such surveil-
lances, however, are difficult to establish and expensive to
maintain. Longitudinal data on HIV status are thus rarely
available [1]. Alternatively, HIV incidence can be estimated from
changes in HIV prevalence over time. The validity of these
estimates, however, depends on assumptions about survival time
distributions among HIV-positive and -negative individuals, which
are commonly quite uncertain [2,3]. Finally, HIV incidence can
be measured in a single cross-sectional survey using laboratory
tests which distinguish recent from non-recent HIV infections,
reducing the need for both longitudinal and repeated cross-
sectional measurement in order to estimate HIV incidence [1].
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In recent years, a number of large-scale cross-sectional HIV
serosurveys have been conducted. For instance, between 2001 and
2008, 20 demographic health surveys (DHS) in developing countries
have included nationally representative HIV serosurveys [4]. A
valid and affordable laboratory procedure to distinguish between
recent and non-recent infections would allow estimation of HIV
incidence in these cross-sectional surveys. One serological method
to differentiate recent from non-recent HIV infections uses the BED
IgG-Capture Enzyme Immunoassay (cBED assay), which measures
the proportion of HIV-1-specific IgG out of total IgG. This
proportion should increase with time after HIV seroconversion [5].
Seropositive individuals who test below a certain threshold of this
proportion (the BED threshold) are classified as recently infected,
while those testing above the BED threshold are classified as non-
recently infected [5]. The time period following seroconversion after
which infections are no longer considered to be recent (the so-called
window period of the cBED assay) is usually estimated at
approximately half a year [5,6,7].
The cBED assay has been used to estimate HIV incidence in
many countries, including in Ethiopia [8], Rwanda [9], South
Africa [10,11], Uganda [12], Zambia [9], Zimbabwe [7], China
[13,14], and the United States [15,16]. However, there has been
concern that the cBED assay-based methods overestimate HIV
incidence to an unknown extent because some non-recent
infections are classified as recent [17]. In some individuals (so-
called non-progressors) the proportion of HIV-1-specific IgG
never rises above the recency threshold, and in other individuals
(so-called regressors) who have been HIV-infected for a long time,
the proportion may fall below the threshold after having previously
progressed above it. Regression to levels below threshold can
occur for a number of biological reasons that decrease HIV-1-
specific IgG relative to total IgG, including viral suppression and
immune reconstitution on antiretroviral treatment (ART), con-
current infections, and late-stage HIV disease [17]. It is in
principle possible to account for non-recently HIV infected
individuals who are misclassified as recently infected, but the
HIV incidence estimates will depend on the estimate of a long-
term false-positive ratio (FPR) [6,7,18]. All current methods for
this correction effectively assume that by some finite time after
HIV infection (the maximum BED progression time) all
individuals, with the exception of non-progressors, will have
progressed to the BED threshold [18]. From previous empirical
observations, it is known that the maximum BED progression time
is of the order of one year [6,7]. Thus, the fraction of all people
who have been HIV-infected at least as long as the maximum
BED progression time who are below the BED threshold is the
long-term FPR.
We use data from a large population-based longitudinal HIV
surveillance to measure the long-term FPR in a rural African
community with high HIV prevalence [19] and HIV incidence
[20], and then compare HIV incidence estimates based on the
cBED assay to estimates based on longitudinal HIV surveillance.
Methods
Setting
We used dried blood spot (DBS) specimens which were collected
in the longitudinal population-based HIV surveillance conducted
by the Africa Centre for Health and Population Studies (Africa
Centre), University of KwaZulu-Natal [21]. The HIV surveillance
area is located near the market town of Mtubatuba in the
Umkhanyakude district of KwaZulu-Natal. The area is 438 square
kilometers in size; it has a population of approximately 85,000
almost exclusively Zulu-speaking people who are members of
about 11,000 households [22]. In 2004, the overall HIV
prevalence among residents in the surveillance area was 27% in
women (15 to 49 years of age) and 14% in men (15 to 54 years of
age) [19]. The surveillance methods have been described
elsewhere [20,23]. Ethics permission for the HIV surveillance at
the Africa Centre was obtained from the Research Ethics
Committee at the College of Health Sciences, University of
KwaZulu-Natal. All participants in the study provided written
informed consent for the analysis of their samples.
Samples
All women aged 15–49 years and all men aged 15–54 years who
were resident in the surveillance area at the time of visit of an HIV
surveillance fieldworker were eligible for HIV testing. Different
samples were used for the different analyses conducted for this
article. The samples for estimation of the long-term FPR consisted
of cBED assay results for blood specimens contributed by
individuals who tested HIV positive in the surveillance in the
time period from June 2003 through June 2006. In order to be
included in the sample, the specimens had to meet the following
criteria. First, they were follow-up specimens from individuals who
had previously tested HIV-positive in the surveillance. Second, the
time period between the first positive HIV test and the follow-up
specimen exceeded the maximum BED progression time. Third,
the specimen was the earliest follow-up specimen that met the
second criterion. Our count of long-term false-positive individuals
included all individuals who were classified as recently HIV-
infected and had been infected for longer than the maximum BED
progression time, i.e. it included both non-progressors and
regressors.
For the further cBED assay analyses we used a maximum BED
progression time of 306 days (sample size n=1,065) as baseline
assumption. In order to assess the sensitivity of the long-term FPR
to the assumed maximum BED progression time, we varied
progression time length from 250 to 400 days in daily intervals.
Table 1 shows sample size and the number of individuals who
were falsely identified as recently HIV-infected for the BED
progression times when the long-term FPR reaches its maximum
and minimum and for all progression times in ten-day intervals
from 250 to 400 days.
For the HIV incidence estimation based on longitudinal HIV
status information, we included all individuals who tested at least
twice for HIV in the period from June 2003 through June 2006
and whose first HIV test in this period was negative (4,869
individuals observed over 7,685 person-years). As in previous
studies of HIV incidence based on data from longitudinal HIV
surveillances [24,25,26,27,28], for the purpose of estimating
exposure time, we used the mid-date between the last available
negative HIV test and the first available positive HIV test as an
estimate of the date of seroconversion. In addition, in order to test
the robustness of the longitudinally measured HIV incidence
estimates to changes in the assumption about seroconversion dates,
we re-estimated HIV incidence using the most extreme assump-
tions about the seroconversion date that are possible given the
interval-censored information on seroconversion dates. At the one
extreme, we assumed that all individuals in the longitudinal sample
who seroconverted did so on the day immediately after the day of
their last HIV-negative test. At the other extreme, we assumed that
all individuals who seroconverted did so on the day of their first
HIV-positive test. Under changes in the assumption of date of
seroconversion, these two extremes yield maximum and minimum
estimates of longitudinally measured incidence.
For the cross-sectional cBED-based HIV incidence estimation,
we used the first available HIV test for all individuals tested in the
cBED Assay-Based HIV Incidence
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time period January 2005 through June 2006 (n=11,755), i.e. the
period in which all second HIV tests of the people included in the
longitudinal HIV incidence analysis took place. Thus, all 4,869
individuals in the longitudinal sample are also included in the
sample for the cBED assay-based analysis.
Laboratory procedures
HIV status was determined by antibody testing with a broad-
based HIV-1/HIV-2 enzyme-linked immunosorbent assay (ELISA;
Vironostika, Organon Teknika, Boxtel, the Netherlands) followed
by a confirmatory ELISA (GAC-ELISA; Abbott, Abbott Park,
Illinois, USA) [23]. If HIV-positive status was confirmed, we used
another spot from the same filter paper as used for the initial test in
order to conduct the cBED assay (cEIA; CalypteH HIV-1 BED
Incidence EIA, Calypte Biomedical Corporation, Maryland, USA).
HIV-specific IgG were detected by the BED-biotin peptide,
followed by a colour reaction with streptavidin-peroxidase. The
optical density values were normalized in every run using a
calibrator (normalized OD (ODn)=mean specimen OD/mean
calibrator OD). Specimens with ODn less than or equal to 1.2
during an initial cBED screening test were confirmed by further
cBED testing of the sample in triplicate. We took the median value
of the three confirmatory test results as the final ODn value. As
specified by the manufacturer, an HIV-1-positive specimen for
which the cBED assay gave a final ODn of less than or equal to 0.8
was considered to be a specimen of recent HIV-1 infection.
Otherwise, the specimen was classified as a non-recent infection [5].
Statistical analysis
Different formulae that use information obtained from the
cBED assay have been proposed to estimate HIV incidence from
cross-sectional surveys. These formulae provide incidence esti-
mates expressed either as a rate, Iˆr, (expressed, for instance, in
number of new HIV infections per 100 person-years) [18] or as the
probability that in a given year a person will acquire HIV, i.e. an
incidence proportion, Iˆp, (expressed, for instance, in number of
new HIV infections per 100 people per year) [6,7]. Some of us
have previously derived a formula from first principles to estimate
HIV incidence based on the cBED assay [18], and have
commented on the assumptions made in different formulae
[29,30]. Here, we implemented four different formulae found in
the literature. The formula for HIV incidence derived by
McDougal and colleagues (McDougal formula) [6] is
I^p~
fR
fRzvN
,
where R is the number of people who were classified as recently
HIV-infected by the cBED assay and N is the number of
individuals who tested HIV-negative. The mean window period of
the cBED assay, v, is ‘‘the mean period of time from initial
seroconversion to reaching an ODn of 0.800’’ expressed in years
in people who progress above the BED threshold [6]. The
‘‘adjustment factor’’
f~ R=Pð Þ{e2½ = R=Pð Þ sze1{2e2ð Þ½ 
takes into account that the cBED assay does not have perfect
specificity or sensitivity, P is the total number of people who tested
HIV-positive, s is the sensitivity of the cBED assay, e1 is the short-
term FPR (i.e. over the period [v, 2v]), and e2 is the long-term
FPR (i.e. over all timesw2v). Note that the short- and long-term
specificities, r1 and r2, are related to the FPRs by r1 = 12e1 and
r2 = 12e2, respectively. The formula of Hargrove and colleagues
Table 1. Long-term FPR.
Maximum BED
progression time Sample size
Number of individuals with false-positive cBED
assay results Long-term FPR (e2)
(in days) (individuals) (individuals) Mean 95% CI
250 1100 18 0.0164 0.0097–0.0257
260 1094 18 0.0165 0.0098–0.0259
270 1090 18 0.0165 0.0098–0.0260
280 1083 18 0.0166 0.0099–0.0261
290 1081 18 0.0167 0.0099–0.0262
300 1070 18 0.0168 0.0100–0.0265
306 1065 18 0.0169 0.0100–0.0266
310 1056 18 0.0170 0.0101–0.0268
320 1043 18 0.0173 0.0103–0.0271
330 1035 18 0.0174 0.0103–0.0273
340 1017 18 0.0177 0.0105–0.0278
350 991 17 0.0172 0.0100–0.0273
360 936 17 0.0182 0.0106–0.0289
370 818 14 0.0171 0.0094–0.0285
374 789 14 0.0177 0.0097–0.0296
380 773 14 0.0181 0.0099–0.0302
390 755 14 0.0185 0.0102–0.0309
400 737 14 0.0190 0.0104–0.0317
FPR = false-positive ratio, CI = confidence interval. Row in bold font shows FPR at twice the window period of 153, 180, and 187 days, respectively.
doi:10.1371/journal.pone.0003640.t001
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(Hargrove formula) [7] is
I^p~
R{e2P
RzvN{e2 PzNð Þ ,
while the formula derived by McWalter and Welte (McWalter/
Welte formula) [18] is
I^r~
R{ e2
1{e2
 
P{Rð Þ
vN
:
In addition, we implemented a simplified version of the
McDougal formula. The adjustment factor used in the formula
can be simplified to
f~ R=Pð Þ{e2½ = R=Pð Þ 1{e2ð Þ½ 
using the identity
sze1{e2~1,
which requires no more assumptions than are used by McDougal
and colleagues [29,30].
Note that in order to implement any of the above four formulae,
estimates of the long-term FPR e2 and the window period v are
required. For our baseline estimation, we use an v of 153 days, i.e.
the window period that is recommended by the manufacturer of
the commercially available cBED assay. Most previous studies
reporting HIV incidence based on the cBED assay have used
window periods between 150 and 160 days
[6,9,12,13,14,15,16,31,32,33,34,35]. A few studies have used a
window period of 180 days [8,10,11], and a recent study from
Zimbabwe calibrated a window period of 187 days in postpartum
mothers enrolled in a Vitamin-A intervention trial [7]. In order to
test whether our results are robust to changes in the window
period estimate, we repeated our analyses with window periods of
180 and 187 days. The Hargrove and McDougal formulae require
that the maximum BED progression time is twice the window
period. The estimate of the long-term FPR thus depends on the
choice of the window period (see Table 1).
Note also that the Hargrove, McWalter/Welte and simplified
McDougal formulae do not require estimates of s and e1, which –
unlike e2 – cannot be calibrated from longitudinal data if the
intervals between the last negative and the first positive HIV test in
seroconverters are of the order of one year [30]. The mean period
of follow-up among seroconverters in our study was 1.4 years; we
thus used estimates of s (0.7680) and e1 (0.2770) from another
study in order to implement the McDougal formula [6] (compare
also [10]).
The McWalter/Welte formula expresses HIV incidence as a
rate, i.e. as the number of HIV seroconversions per person-time at
risk, while all other formulae express HIV incidence as an
incidence proportion, i.e. the number of HIV seroconversions
within a specified time period divided by the size of the population
initially at risk. In order to directly compare all HIV incidence
estimates in our study, we expressed the estimates based on the
McWalter/Welte formula and the longitudinally measured HIV
incidence both as rates (per 100 person-years) and as incidence
proportions (per 100 people per year). We translated the rate
estimates into proportions, assuming that the incidence rate, Iˆr, is
constant over time T, by using the relationship
I^p~1{e
{I^ rT :
The authors of the four different formulae do not use equivalent
methods for the calculation of confidence intervals (CIs). Thus,
uncertainty analysis on the incidence estimates was performed as
follows. Any observed proportion of HIV-negative, cBED-recent
and cBED-non-recent individuals is an unbiased estimate of the
underlying population proportions. Given an observed occurrence
of the population proportions and the sample size, all attainable
draws of the three counts can be enumerated and assigned their
respective trinomial probability. Hence an exact cumulative
probability distribution of attainable values of the incidence
estimator can be computed. For each incidence estimate, we quote
the estimator evaluated at the observed counts (the maximum
likelihood estimate) and a confidence interval expressed as the
central 95th percentile.
To control for differences in the sex-age composition between
the sample used in the longitudinal HIV incidence estimation and
the sample used in the cBED assay-based estimation, we weighted
the sex- and five-year age group-specific longitudinal mean
incidence rates by the proportions of individuals in each of the
sex-age groups in the sample used for the cBED assay-based
estimation
I^rs~
X
i
wsi I^ ri,
where Iˆrs is the sex-age adjusted mean incidence rate, wsi are the
proportions of individuals in each sex-age group in the cBED assay
sample, and Iˆri are the sex-age specific mean incidence rates. We
estimated the variance of Iˆrs, var(Iˆrs), as
var I^ rs
 
~
X
i
w2si
I^2ri
C^i
assuming that the number of HIV incident cases, Cˆi, is Poisson
distributed [36]. We calculated the 95% confidence limits for Iˆrs
using the method based on gamma distributions described in
Anderson and Rosenberg [37].
Results
Long-term FPR
Counting the number of DBS specimens classified as recently
HIV-infected by the cBED assay in the sample of all individuals
who had a previous positive HIV test more than 306 days before
the date of the cBED assay-tested specimen, we obtained a long-
term FPR of 0.0169 (95% CI 0.0100–0.0266). When we varied the
length of the maximum BED progression time from 250 to 400
days (in daily intervals), we found that the estimate of the long-
term FPR did not change significantly over the time interval, with
minimum and maximum long-term FPRs of 0.0164 (95% CI
0.0097–0.0257) and 0.0190 (95% CI 0.0104–0.0317), respectively
(Table 1).
Incidence comparison
Of the 4,869 individuals included in the sample for longitudinal
HIV incidence measurement, 224 people seroconverted in 7,685
person-years. Assuming that seroconversion occurred at the mid-
date between the last available negative HIV test and the first
cBED Assay-Based HIV Incidence
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available positive HIV test, longitudinally measured crude HIV
incidence was 2.87 per 100 people per year (95% CI 2.53–3.27)
(Table 2). Longitudinally measured HIV incidence increased to
3.09 per 100 people per year (95% CI 2.69–3.52), when we
adjusted it to the age-sex distribution of the sample for the cBED
assay-based incidence estimate.
Of the 11,755 individuals included in the sample for the cBED
assay-based HIV incidence measurement, 9,236 tested HIV-
negative and 2,519 HIV-positive. Of the individuals who tested
HIV-positive, 165 were classified in cBED assay testing as recently
HIV-infected and the remainder as non-recently infected. For
given e2 and v, the four different formulae to calculate HIV
incidence from cBED assay measurement produced very similar
results. Using the baseline estimate for v of 153 days and the
locally measured e2 of 0.0169, HIV incidence point estimates (per
100 people per year) varied between 3.03 (95% CI 2.44–3.63;
McDougal formula) and 3.19 (95% CI 2.57–3.82; Hargrove
formula) (Table 2). The cBED assay-based HIV incidence
estimates were thus very similar in magnitude and did not differ
significantly from the estimates based on longitudinal measure-
ment (crude and sex-age adjusted) (Table 2). Furthermore, when
we implemented the cBED assay formulae using the lower bound
or upper bound of the 95% CI of the locally measured long-term
FPR (0.0100–0.0266), the cBED assay-based HIV incidence
estimates did not differ significantly from the estimates based on
longitudinal measurement. By contrast, when we implemented the
cBED assay formulae using the externally measured long-term
FPR of 0.0560 [6], all four cBED assay-based HIV incidence
estimates were significantly lower than the longitudinal estimates
(Table 2).
Our finding that the cBED assay-based HIV incidence estimate
was not significantly different from the longitudinal HIV incidence
Table 2. HIV incidence estimates.
Estimation type Unit HIV incidence
Mean 95% CI
Longitudinal measurement
(7,685 person-years, 224 seroconversions)
Crude (per 100 person-years) 2.91 2.56–3.32
Sex-age adjusted (per 100 person-years) 3.14 2.73–3.58
Crude (per 100 people per year) 2.87 2.53–3.27
Sex-age adjusted (per 100 people per year) 3.09 2.69–3.52
cBED assay measurement
(n=11,755)
Mean of locally measured long-term FPR (e2 = 0.0169)
McWalter/Welte (per 100 person-years) 3.22 2.57–3.87
McWalter/Welte (per 100 people per year) 3.17 2.54–3.80
McDougal (per 100 people per year) 3.03 2.44–3.63
Hargrove (per 100 people per year) 3.19 2.57–3.82
McDougal, simplified (per 100 people per year) 3.12 2.51–3.73
Lower bound of 95% CI of locally measured long-term FPR (e2 = 0.0100)
McWalter/Welte (100 person-years) 3.65 3.00–4.32
McWalter/Welte (per 100 people per year) 3.58 2.95–4.22
McDougal (per 100 people per year) 3.40 2.82–4.00
Hargrove (per 100 people per year) 3.57 2.95–4.19
McDougal, simplified (per 100 people per year) 3.52 2.91–4.14
Upper bound of 95% CI of locally measured long-term FPR (e2 = 0.0266)
McWalter/Welte (100 person-years) 2.60 1.96–3.27
McWalter/Welte (per 100 people per year) 2.57 1.94–3.22
McDougal (per 100 people per year) 2.49 1.89–3.11
Hargrove (per 100 people per year) 2.63 1.99–3.29
McDougal, simplified (per 100 people per year) 2.53 1.92–3.17
Externally measured long-term FPR (e2 = 0.0560)
McWalter/Welte (100 person-years) 0.65 0.00–1.33
McWalter/Welte (per 100 people per year) 0.65 0.00–1.32
McDougal (per 100 people per year) 0.66 0.00–1.33
Hargrove (per 100 people per year) 0.71 0.00–1.43
McDougal, simplified (per 100 people per year) 0.65 0.00–1.32
CI = confidence interval, FPR = false-positive ratio.
doi:10.1371/journal.pone.0003640.t002
cBED Assay-Based HIV Incidence
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estimate did not change when we applied the window periods of
180 and 187 days (and their corresponding long-term FPRs of
0.0182 and 0.0177 (see Table 1)). Using the McWalter/Welte
formula, the cBED assay-based HIV incidence was estimated at
2.63 per 100 people per year (95% CI 2.10–3.18) with a 180-day
window period and at 2.56 per 100 people per year (95% CI 2.04–
3.08) with a 187-day window period. Neither of these estimates
was significantly different from the longitudinally measured HIV
incidence estimates or from the cBED assay-based incidence
estimates based on a 153-day window period (see Table 2).
As described above, we conducted sensitivity analysis of the
longitudinally measured HIV incidence estimate by changing the
assumption about seroconversion dates. Assuming that all
seroconverters became HIV-seropositive on the day following
the last negative HIV test, crude HIV incidence was estimated at
2.97 per 100 person-years (95% CI 2.61–3.39). Assuming, on the
other hand, that all seroconverters became HIV-seropositive on
the day of their first positive HIV test, crude HIV incidence was
estimated at 2.85 per 100 person-years (95% CI 2.51–3.25). The
longitudinal HIV incidence estimates were thus highly robust to
changes in the approach to computing the seroconversion date.
Even under the most extreme possible assumptions, the mean HIV
incidence changed by only 2% of the estimate based on the mid-
date assumption, as reported in Table 2.
When we stratified HIV incidence by sex and five-year age group
(starting at 15 years of age), we found that none of the cBED assay-
based sex and age-specific estimates differed significantly from the
corresponding longitudinally measured sex and age-specific esti-
mates. However, our samples in each of the sex-age groups were too
small to detect significant differences with reasonable confidence.
The coefficients of variation (CVs) of the sex-age specific cBED
assay-based HIV incidence estimates ranged from 18% to 203%; in
13 of the 15 sex-age groups the CVs were larger than 25%; in 10
sex-age groups the CVs were larger than 50%; and in 4 sex-age
groups they were larger than 100%.
Discussion
In a rural community in South Africa, we found a long-term FPR
of the cBED assay of 0.0169. This value is substantially lower than
the two previous estimates of the ratio. The first estimate (0.0560)
‘‘was based on analysis of specimens from longer-term-infected
individuals not known to have clinical AIDS, opportunistic
infections, or to be on treatment’’ in the USA [6]. The article, in
which this value was published, provides neither the sample size for
the measurement nor the confidence limits around the estimate [6].
Thus we cannot test whether the estimate is significantly different
from the value that we measure in rural South Africa. The second
estimate (0.0520) was based on specimens from 2,749 postpartum
mothers enrolled in a Vitamin-A intervention trial in Zimbabwe [7].
This second estimate was significantly higher than the value
measured in our study (p,0.0001).
Many previous studies have used the first estimate of the long-
term FPR in their estimations of HIV incidence based on cross-
sectional cBED assay surveys (e.g. [9,10,12,14]). In comparing
cBED-based HIV incidence estimates to HIV incidence measured
longitudinally in the same population, we have demonstrated that,
had we used the long-term FPR of 0.0560, we would have
significantly underestimated HIV incidence in this community. By
contrast, using the locally measured ratio of 0.0169, we estimated
an HIV incidence that does not differ significantly from the
longitudinally measured incidence.
Our findings thus confirm the previous results by McDougal et
al. [6] and Hargrove et al. [7] that cBED assay-based HIV
incidence estimates are not significantly different from longitudi-
nally measured HIV incidence, when a locally calibrated long-
term FPR ratio is used to adjust for the imperfect long-term
specificity of the cBED assay. At the same time, we have shown for
the first time that the long-term FPR differs significantly across
settings. Hence, results from studies that use a long-term FPR
measured in another setting should be viewed with skepticism.
We further found that the different formulae to estimate HIV
incidence based on the cBED assay results, did not produce
significantly different values even though they differ in their
underlying assumptions, suggesting that the choice of formula may
not be very important for most practical purposes. Finally, we
showed that the estimates of the long-term FPR based on data
from a longitudinal HIV surveillance are very robust to changes in
the definition of ‘‘long-term’’ (i.e. the choice of the maximum BED
progression time).
Our longitudinal HIV incidence estimates in this article are
slightly lower than previously published estimates from the same
community [20], because the current study uses a sample that is
different from the one used previously. In particular, unlike in the
previous study, we excluded from the sample people who were
identified as members of a household in the study area, but who
did not themselves live in the area. We excluded this population
group (which faces a significantly higher risk of HIV acquisition
than household members who live in the study area [23]), because
cross-sectional cBED assay surveys usually do not trace such non-
resident household members.
HIV incidence estimates by sex and age group are important for
validating the cBED assay method as an approach to measure
HIV incidence [7], and are an important disaggregation for health
policy and planning, e.g. in order to inform the targeting of HIV
prevention interventions. Our current sample lacked the statistical
power to meaningfully stratify the HIV incidence estimates. As
more data becomes available from our site, we will in the future
analyze HIV incidence across population subgroups.
The promise of the cBED assay for HIV surveillance, program
evaluation and policy making, lies in the fact that it allows HIV
incidence estimation from cross-sectional samples. Cross-sectional
HIV status information, however, does not permit estimation of
the long-term FPR, requiring researchers to obtain this parameter
independently. It is thus important that the parameters necessary
for HIV incidence estimation are calibrated using data from those
settings where longitudinal follow-up is available. A meta-analysis
of the long-term FPR of the cBED assay may help explain why the
parameter estimates differ and allow the determination of valid
regional parameter estimates.
It may further be necessary to measure the long-term FPR
repeatedly over time. For instance, one of the reasons why people
with non-recent HIV infections are falsely classified as recently
infected by the cBED assay is viral suppression due to ART [38]. In
October 2004, ART started to become available through the public
health services in the community in which this study took place.
However, only a very small number of patients received ART during
the study period. By the end of December 2005, i.e. half a year before
the end of the study period, approximately 500 patients received
ART through the public ART programme in the district in which this
study took place. Because the HIV surveillance covers less than half of
the district population, we estimate that in December 2005 less than
250 people in the surveillance area were receiving ART out of a total
resident population of approximately 65,000 [39]. Future studies will
need to investigate whether our locally estimated cBED long-term
FPR changes with increasing ART coverage.
An alternative to using the long-term FPR in order to adjust
cBED assay-based HIV incidence estimates for the presence of
cBED Assay-Based HIV Incidence
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people who are falsely classified as recently HIV-infected is to use
additional information on time since seroconversion to identify
these individuals and correct the misclassification. Information on
time since seroconversion, which can be obtained in cross-
sectional surveys, could be based on biological parameters that
change with time since infection (such as CD4 count, total
lymphocyte count, or viral load), clinical assessment (such as
screening for HIV-related diseases that indicate late-stage HIV
disease [40]), and screening for ART (through a question or
laboratory test).
In conclusion, our study demonstrates that without a locally
measured long-term FPR HIV incidence estimates based on the
cBED assay may be severely biased, but that the cBED assay
performs well in HIV incidence estimation, if a locally appropriate
long-term FPR is used.
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